Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Soleno Therapeutics, Inc. is not very popular among insiders. Soleno Therapeutics, Inc. is a mediocre stock to choose.

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for...

News

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of "Buy" by Brokerages

Ticker Report Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are currently covering the stock, MarketBeat...\n more…

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of "Buy" by Analysts

Zolmax Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat...\n more…

Soleno Therapeutics (NASDAQ:SLNO) Now Covered by Analysts at HC Wainwright

Ticker Report Equities researchers at HC Wainwright started coverage on shares of Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage set a "buy...\n more…

Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at HC Wainwright

Zolmax HC Wainwright assumed coverage on shares of Soleno Therapeutics (NASDAQ:SLNO - Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating...\n more…

Soleno Therapeutics initiated with bullish view at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

James H. Mackaness Sells 6,661 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock

Ticker Report Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CFO James H. Mackaness sold 6,661 shares of Soleno Therapeutics stock in a transaction that occurred on Wednesday, August 28th. The stock was...\n more…